{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:36:20Z","timestamp":1777613780371,"version":"3.51.4"},"reference-count":9,"publisher":"Wiley","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"crossref","award":["I01 RX000194"],"award-info":[{"award-number":["I01 RX000194"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"crossref","award":["P30DK41301"],"award-info":[{"award-number":["P30DK41301"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["I01 RX000194"],"award-info":[{"award-number":["I01 RX000194"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK41301"],"award-info":[{"award-number":["P30DK41301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Reports in Gastrointestinal Medicine"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a patient with AS and previously undiagnosed IBD, found to be in a severe ulcerative colitis flare shortly after receiving the loading dose of secukinumab. There are no guidelines regarding biologic salvage therapy for IBD in the setting of active treatment with another biologic agent. After waiting one half-life of secukinumab, our patient had an excellent response to initiation of infliximab.<\/jats:p>","DOI":"10.1155\/2018\/9679287","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T18:31:48Z","timestamp":1518719508000},"page":"1-4","source":"Crossref","is-referenced-by-count":21,"title":["A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis"],"prefix":"10.1155","volume":"2018","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-8429","authenticated-orcid":true,"given":"Dean","family":"Ehrlich","sequence":"first","affiliation":[{"name":"Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimah","family":"Jamaluddin","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Pisegna","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"},{"name":"Division of Gastroenterology, Hepatology and Parenteral Nutrition, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-9939","authenticated-orcid":true,"given":"David","family":"Padua","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"},{"name":"Division of Gastroenterology, Hepatology and Parenteral Nutrition, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","year":"2015"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1505066"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-eular.3684"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12267"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12118"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.355"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20014"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2003.09.013"}],"container-title":["Case Reports in Gastrointestinal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/crigm\/2018\/9679287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crigm\/2018\/9679287.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crigm\/2018\/9679287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T12:34:31Z","timestamp":1526646871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/crigm\/2018\/9679287\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":9,"alternative-id":["9679287","9679287"],"URL":"https:\/\/doi.org\/10.1155\/2018\/9679287","relation":{},"ISSN":["2090-6528","2090-6536"],"issn-type":[{"value":"2090-6528","type":"print"},{"value":"2090-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}